Bank Of America Corp Cidara Therapeutics, Inc. Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.68 - $0.97 $36 - $51	53 New	53 $0
Q1 2023 May 12, 2023	BUY	$0.75 - $1.98 $429 - $1,134	573 Added 379.47%	724 $0
Q4 2022 Feb 10, 2023	BUY	$0.48 - $0.76 $72 - $114	151 New	151 $0
Q2 2022 Aug 12, 2022	SELL	$0.43 - $0.91 $3,903 - $8,260	-9,077 Reduced 26.51%	25,157 $12,000
Q1 2022 May 16, 2022	BUY	$0.67 - $1.39 $24 - $51	37 Added 0.11%	34,234 $28,000

Q4 2021 Feb 08, 2022	SELL	$1.18 - $2.18 $2,142 - $3,958	-1,816 Reduced 5.04%	34,197 $43,000
Q3 2021 Nov 15, 2021	SELL	$1.48 - $2.35 $8,542 - $13,564	-5,772 Reduced 13.81%	36,013 $81,000
Q2 2021 Sep 13, 2021	BUY	$1.87 - $2.7 $78,137 - $112,819	41,785 New	41,785 $84,000

22.1M

2.7K

100

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $889M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.